Biotoxtech Reports Q1 2026 Consolidated Operating Loss of 1.82 Billion KRW; Net Debt-to-Equity Ratio Soars to 158.6%

Consolidated Q1 2026 revenue: KRW 11.87bn (+5.5% YoY from 11.25bn), operating loss: KRW 1.82bn (widened from KRW 1.62bn loss in Q1 2025)
Consolidated net loss: KRW 2.71bn, controlling interest net loss: KRW 1.87bn, basic EPS loss: KRW 121
Total liabilities: KRW 100.81bn, equity: KRW 29.25bn, net debt-to-equity ratio: 158.6% (up from 136.7% at end-2025)
Standalone revenue: KRW 7.43bn (+3.4% YoY), operating loss: KRW 0.99bn, net loss: KRW 1.08bn
Consolidated derivative liabilities (convertible bonds, bonds with warrants, etc.): KRW 17.10bn, concentrated debt maturity risk
Major shareholders: CEO and related parties 23.45%, Celltrion 10.22%
No share buyback/cancellation or dividend disclosed